Mustang Bio - MBIO STOCK NEWS

Mustang Bio, Inc. (NASDAQ: MBIO) reported Q1 2021 financial results, highlighting significant clinical advancements. The FDA lifted a CMC hold on the MB-107 IND for infants with XSCID, enabling patient dosing soon. The company announced progress on MB-106, a CAR T cell therapy, with FDA approval to conduct a Phase 1/2 trial for B-NHL and CLL. As of March 31, 2021, cash equivalents totaled $130.4 million, up from $98.8 million at year-end 2020. Despite increased R&D and G&A expenses, the net loss was $15 million, or $0.19 per share.

Mustang Bio (NASDAQ: MBIO) announced that updated interim data from the Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T therapy, will be presented at the European Hematology Association 2021 Virtual Congress. The trial, conducted in collaboration with Fred Hutch, reported an overall response rate of 92% among 12 patients, with a complete response rate of 58%. Cytokine release syndrome occurred in 25% of patients, with manageable symptoms. The findings highlight the therapy's favorable safety profile compared to existing treatments.

Mustang Bio (NASDAQ: MBIO) announced the FDA's acceptance of its IND application for MB-106, a CAR T therapy targeting CD20 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The Phase 1/2 multicenter trial is set to begin recruiting patients in Q3 2021. Previous studies indicated a favorable safety profile for MB-106, with an 89% overall response rate. With NHL and CLL accounting for significant cancer cases in the U.S., Mustang aims to provide effective treatment options for these patients.

Mustang Bio, a clinical-stage biopharmaceutical company (NASDAQ: MBIO), will participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit on April 26-27, 2021. CEO Manuel Litchman and CTO Knut Niss will be featured in a fireside chat on April 26 at 3:15 p.m. ET, with webcasts available on Mustang's website for 30 days post-event. The company focuses on cell and gene therapies for hematologic cancers and rare diseases, partnering with leading institutions to advance CAR T technologies.

Mustang Bio, Inc. (NASDAQ: MBIO) announced its financial results for the year ending December 31, 2020, highlighting robust progress in its cell and gene therapy programs. Notable achievements include MB-106 showing an 89% overall response rate and 44% complete response rate in B-cell non-Hodgkin lymphoma trials. Financially, Mustang reported cash reserves of $98.8 million, up from $62.4 million in 2019. Despite increased R&D expenses totaling $37.2 million, the net loss rose to $60 million, or $1.14 per share. Looking ahead, Mustang plans to advance multiple clinical trials in 2021, targeting innovative therapies for rare diseases.

Mustang Bio, Inc. (NASDAQ: MBIO) announced its management team's participation in three virtual investor conferences in March 2021. The events include:

• H.C. Wainwright Global Life Sciences Virtual Conference on March 9, 2021, available on-demand.
• Oppenheimer 31st Annual Virtual Healthcare Conference on March 16, 2021, with a fireside chat at 3:10 p.m. ET.
• Redburn Virtual Gene Therapy Summit on March 31, 2021, at 9:15 a.m. ET.

Webcasts will be accessible on Mustang's website for 30 days following each event.

Mustang Bio (NASDAQ: MBIO) supports Rare Disease Day on February 28, aiming to enhance awareness of rare diseases. The company is committed to advancing treatments for conditions like X-linked severe combined immunodeficiency (XSCID) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Two pivotal clinical trials for XSCID are set to begin this year, RESTORE and SUSTAIN, targeting young patients and those with prior stem cell transplants. Mustang's initiatives also include partnerships with patient advocacy groups. The company acknowledges the challenges faced by individuals with rare diseases as they work towards potential cures.

Mustang Bio, a clinical-stage biopharmaceutical company (NASDAQ: MBIO), announced its CEO, Manuel Litchman, will participate in three upcoming virtual investor conferences in January 2021. These include the 10th Annual LifeSci Partners Corporate Access Event from January 6-14, the H.C. Wainwright Virtual BioConnect Conference on January 11, and the B. Riley Securities’ Virtual Oncology Investor Conference on January 21. Presentations will be available on Mustang's website for 30 days following the events. Mustang focuses on cell and gene therapies for cancers and rare diseases.

Mustang Bio (NASDAQ: MBIO) has initiated a Phase 1 clinical trial at City of Hope to evaluate the safety and feasibility of MB-101 (IL13Rα2-CAR T cells) in treating patients with leptomeningeal brain tumors, including glioblastoma, ependymoma, and medulloblastoma. The trial will involve up to 30 patients and will assess toxicity and survival at three months, with additional secondary endpoints. The therapy previously showed promising results, including a complete response in a glioblastoma patient. The trial aims to provide a potential new treatment for these difficult-to-treat cancers.